Kavanaugh A, McInnes I, Mease P et al. Arthritis Rheum 2009;60:976–86.
The aim of these investigators was to determine the efficacy and safety of the anti-tumor necrosis factor-α agent golimumab in patients with active psoriatic arthritis (PsA) in a randomized, double-blind, placebo-controlled trial. At 14 weeks, the primary endpoint of a 20% improvement in American College of Rheumatology criteria was achieved by significantly more golimumab-treated patients than placebo recipients (p<0.001). Significant improvements in secondary endpoints (including Psoriasis Area and Severity Index for skin, and Nail Psoriasis Severity Index for nails) were also achieved in golimumab recipients compared with placebo recipients.
The GO-REVEAL (Golimumab – a Randomized Evaluation of Safety and Efficacy in Subjects with Psoriatic Arthritis Using a Human Anti-TNF Monclonal Antibody) study was designed to investigate the safety and efficacy of the new anti-tumor necrosis factor-α (anti-TNF-α) drug golimumab in patients with psoriatic arthritis (PsA). Outcome measures of efficacy in improving clinical outcomes in the skin, nails, and joints were reported.